Core Viewpoint - Haofan Bio's aggressive acquisition of a loss-making pharmaceutical company highlights the capacity constraints faced by biopharmaceutical firms, reflecting a broader industry challenge in managing production capabilities [1][5]. Group 1: Acquisition Details - Haofan Bio plans to invest 160 million yuan to fully acquire Hangzhou Foster Pharmaceutical in two phases, gaining 85% control after the first phase [2]. - The urgency of this acquisition stems from Haofan Bio's production capacity being fully utilized at its Anhui base, with a lengthy construction period for its new facility in Huai'an [2]. Group 2: Financial Performance of Target Company - Hangzhou Foster reported a revenue of 204 million yuan in 2024 but incurred a net loss exceeding 28 million yuan, with losses continuing into the first quarter of 2025 [3]. - Despite having a net asset value of only 46.03 million yuan, the acquisition was valued at 162 million yuan, resulting in a staggering premium of 251.52% [3]. Group 3: Strategic Intentions Behind the Acquisition - Haofan Bio's acquisition strategy includes vertical integration to enter the intermediate and active pharmaceutical ingredient sectors, thereby extending its industrial chain [4]. - The company aims to alleviate its delivery crisis by acquiring existing GMP production capacity and enhance its CDMO service capabilities through the integration of the target's quality management systems [4]. Group 4: Industry Context and Challenges - The aggressive acquisition by Haofan Bio is indicative of a broader trend in the pharmaceutical industry, where companies face "capacity anxiety" due to the high costs and long timelines associated with building production facilities [5]. - The strategy of acquiring loss-making assets can potentially open up capacity but also poses risks of integration challenges, emphasizing the need for strategic discipline and risk management in navigating industry cycles [5].

Core Viewpoint - The announcement details the unlocking of a portion of pre-IPO shares of Suzhou Haofan Biological Co., Ltd., which will be released from a 24-month lock-up period starting from July 14, 2025, allowing for increased liquidity in the company's stock [1][3]. Group 1: Pre-IPO Share Issuance Overview - The company received approval from the China Securities Regulatory Commission for an initial public offering (IPO) of 27,000,000 shares, which began trading on July 12, 2023 [1]. - Prior to the IPO, the total share capital of the company was 108,000,000 shares, with 23,394,744 shares subject to lock-up, representing 21.66% of the total post-IPO share capital [1]. - The total number of locked shares is 84,605,256, accounting for 78.34% of the total post-IPO share capital [1]. Group 2: Locked Shares Release Details - A total of 1,863,000 shares, representing 1.73% of the total share capital, will be released from lock-up on July 14, 2025 [3]. - The shareholders applying for the release of locked shares include four individuals, who have committed to adhere to lock-up agreements [3][5]. - The company has confirmed that there have been no changes in share capital due to issuance, repurchase, or stock dividends since the IPO [3]. Group 3: Compliance and Commitments - The shareholders have made commitments to not transfer or manage their shares for 12 months post-IPO and to comply with relevant regulations regarding share transfers and reductions [4]. - The shareholders have fulfilled their commitments, ensuring that there are no outstanding obligations affecting the release of locked shares [5]. - The company will monitor compliance with share reduction commitments and disclose shareholder compliance in regular reports [5]. Group 4: Share Capital Structure Changes - Following the release of locked shares, the structure of the company's share capital will change, with locked shares decreasing to 65,895,225, representing 61.01% of the total [5]. - The number of unrestricted shares will increase to 42,104,775, accounting for 38.99% of the total share capital [5]. - The total share capital remains unchanged at 108,000,000 shares [5].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 苏州昊帆生物股份有限公司 关于现金购买杭州福斯特股权的进展公告 证券代码：301393 证券简称：昊帆生物 公告编号：2025-036 名称：杭州福斯特药业有限公司 统一社会信用代码：913301827319937397 类型：有限责任公司 自然人投资或控股） 1 住所：浙江省杭州市建德市梅城镇新胜路 17 号 法定代表人：贺亚 为进一步提高公司的规模化供应能力和质量管理水平，解决公司产能瓶颈问 题，苏州昊帆生物股份有限公司（ 以下简称（ 公司"或（ 昊帆生物"）于 2025 年 7 月 4 日召开了第四届董事会第十次会议和第四届监事会第八次会议，审议通过 了《关于公司以现金方式收购杭州福斯特药业有限公司 100%股权的议案》，同 意公司以自有或自筹资金向上海予君生物科技发展有限公司（ 以下简称（ 予君生 物"）、徐竹清等 11 名交易对方购买其持有的杭州福斯特药业有限公司 以下 简称 杭州福斯特" 标的公司"）100%的股权，转让价格为 16,000 万元。股 权转让分两期进行：第一期转让标的公司 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-035 苏州昊帆生物股份有限公司 关于开立募集资金现金管理专用结算账户 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第四届董事会第七次会议及第四届监事会第五次会议，并于 2025 年 5 月 9 日召 开 2024 年度股东大会，审议通过了《关于使用闲置募集资金和闲置自有资金进 行现金管理的议案》，同意公司使用额度不超过 10 亿元的闲置募集资金和不超 过 14 亿元的闲置自有资金进行现金管理。使用期限自股东大会审议通过之日起 12 个月内有效。在前述额度和期限内，资金可以循环滚动使用。具体内容详见 公司于 2025 年 4 月 11 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于使用 闲置募集资金和闲置自有资金进行现金管理的公告》（公告编号：2025-014）。 近日，公司开立了闲置募集资金现金管理专用结算账户，具体如下： | 账户名称 | 账号 | 开户机构 | | --- | -- ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-031 苏州昊帆生物股份有限公司 （一）首次公开发行股份情况 部分首次公开发行前已发行股份上市流通 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次上市流通的限售股份为苏州昊帆生物股份有限公司（以下简称"公 司"或"昊帆生物"）部分首次公开发行前已发行股份，限售期为自公司首次公 开发行股票并上市之日起 24 个月。 2、因本次解除限售的股东自愿承诺延长部分股份的锁定期限，其持有的公 司首次公开发行前股份分四批次解锁，每批次解锁的比例为本人持有的公司首次 公开发行前股份的 25%，各批次解锁时间分别为自公司股票上市之日起 12 个月、 24 个月、36 个月、48 个月。截至 2025 年 7 月 14 日，公司股票上市已满 24 个 月，满足第二批次股份的解锁条件。 3、本次解除限售的股东户数为 4 户，股份数量为 1,863,000 股，占公司总股 本的 1.73%。 4、本次解除限售股份的上市流通日期为 2025 年 7 月 14 日（星期一）。 一、首次公开发 ...

民生证券股份有限公司 关于苏州昊帆生物股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 民生证券股份有限公司（以下简称"民生证券"、"保荐人"）作为苏州昊帆 生物股份有限公司（以下简称"昊帆生物"、"公司"）首次公开发行股票并在创 业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板股票上市 规则》等有关规定，对昊帆生物部分首次公开发行前已发行股份上市流通事项进 行了核查，具体情况如下： 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意苏州昊帆生物股份有限公司首次公开 发行股票注册的批复》（证监许可[2023]806 号）同意注册，并经深圳证券交易所 同意，公司首次公开发行 27,000,000 股人民币普通股（A 股），于 2023 年 7 月 12 日在深圳证券交易所创业板上市交易。首次公开发行前公司总股本为 81,000,000 股，首次公开发行股票完成后公司总股本为 108,000 ...

Core Viewpoint - Haofan Bio plans to acquire 100% equity of Hangzhou Foster Pharmaceutical for 160 million RMB to overcome production capacity constraints and enhance supply capabilities [1][2][3] Group 1: Acquisition Details - The acquisition will be conducted in two phases, with the first phase granting Haofan Bio 85% equity, making it the controlling shareholder [3] - Hangzhou Foster is a mature production base with complete production and supporting facilities, certified by GMP, ISO9001, ISO14001, and OHSAS18001 [3][4] - The acquisition aims to leverage Hangzhou Foster's existing surplus capacity to improve Haofan Bio's supply capabilities and product structure [4] Group 2: Financial Performance - Hangzhou Foster reported a revenue of 204 million RMB in 2024 with a net loss of 28.44 million RMB, and a revenue of 26.18 million RMB in Q1 2025 with a net loss of 8.44 million RMB [5] - Haofan Bio experienced significant growth in 2024, achieving a revenue of 452 million RMB, a 16.22% increase year-on-year, and a net profit of 134 million RMB, a 35.44% increase [7] Group 3: Market Context - Haofan Bio has been facing production capacity shortages due to increased market demand, which has hindered its ability to fulfill customer orders [6] - The company is actively working on expanding its production capacity through new projects and collaborations, aiming to increase its self-owned capacity over the next 2-3 years [7]

Core Viewpoint - Suzhou Haofan Bio Co., Ltd. plans to acquire 100% equity of Hangzhou Foster Pharmaceutical Co., Ltd. for 160 million yuan, aiming to enhance its production capacity and product offerings despite the target company's current losses [1][4][11]. Group 1: Acquisition Details - The acquisition will occur in two phases, with the first phase granting Haofan Bio 85% equity, making it the controlling shareholder [1]. - The total transaction price is set at 160 million yuan, based on an asset-based valuation of 97.02 million yuan and a revenue-based valuation of 161.81 million yuan, indicating a significant premium [5][6]. Group 2: Financial Performance of Target Company - Hangzhou Foster reported revenues of 203.69 million yuan and 26.18 million yuan for 2024 and Q1 2025, respectively, with net losses of 28.44 million yuan and 8.44 million yuan [3][4]. - As of March 31, 2025, Hangzhou Foster's total assets were 268.74 million yuan, with total liabilities of 222.71 million yuan, resulting in a net asset value of 46.03 million yuan [3]. Group 3: Strategic Rationale - The acquisition is expected to allow Haofan Bio to leverage Hangzhou Foster's excess production capacity and certifications, enhancing operational efficiency and market competitiveness [12]. - The move aligns with Haofan Bio's strategy to expand its product structure and create new business and profit growth points, especially as its current production capacity is insufficient to meet demand [11][12].

Core Viewpoint - Haofan Bio is facing capacity bottlenecks and has proposed an acquisition plan to enhance its production capacity, despite the target company reporting losses in the past year and the first quarter of this year [1][3]. Group 1: Acquisition Details - Haofan Bio plans to use 160 million yuan of its own or raised funds to acquire 100% equity of Hangzhou Foster Pharmaceutical Co., Ltd. The acquisition will occur in two phases, with the first phase granting Haofan Bio 85% equity and the second phase achieving full ownership [1][3]. - Hangzhou Foster specializes in the research, production, and sales of advanced intermediates and specialty APIs, focusing on oncology, antiviral, allergy, cardiovascular, and psychiatric medications [1][3]. Group 2: Strategic Rationale - The acquisition will allow Haofan Bio to extend its product chain into downstream intermediates and APIs, enriching and optimizing its product structure, and creating new business and profit growth points [3]. - The target company has established a GMP-compliant production and quality management system, which will enhance Haofan Bio's quality management capabilities and overall service capacity [3]. - The acquisition is expected to facilitate resource sharing and market synergy between Haofan Bio and Hangzhou Foster, enhancing customer resource and sales channel integration [3]. Group 3: Financial Performance of Target Company - Hangzhou Foster reported a revenue of 204 million yuan in 2024 with a net loss of 28.44 million yuan, and for the first quarter of 2025, it generated a revenue of 26.18 million yuan with a net loss of 8.44 million yuan [4]. - The company has been facing cash flow challenges, with negative cash flow from operating activities reported [4]. Group 4: Valuation and Premium - The acquisition involves a premium, with the assessed value of Hangzhou Foster's equity at 162 million yuan, reflecting a 251.52% increase over its book value of 46.03 million yuan [5]. - The premium is justified based on the asset's growth potential and market positioning, although significant premiums warrant caution from management and investors [5].

证券代码：301393 证券简称：昊帆生物 公告编号：2025-032 苏州昊帆生物股份有限公司 关于现金购买杭州福斯特股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司拟使用 16,000 万元人民币自有或自筹资金，购买杭州福斯特药业有 限公司 100%股权（以下简称"本次收购"、"本次交易"）。本次收购分两期 进行，第一期股权转让完成后公司将获得标的公司 85%股权，成为其控股股东； 第二期股权转让完成后公司将获得标的公司 100%股权。 2、第二期股权转让在第一期股权转让工商变更后 24 个月内实施。 3、本次交易已经公司董事会审议通过，无需提交股东大会审议。本次交易 不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 4、标的公司最近一个会计年度存在亏损情形，若交易完成后公司无法充分 利用标的公司的富余产能及资质优势，发挥协同效应，或若未来持续存在宏观经 济波动、行业竞争加剧、原材料价格上涨、客户需求不及预期等不利因素，标的 公司存在持续亏损的风险，提请投资者注意相关风险。 一、交易概述 为进一 ...